These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26828214)

  • 1. N30 Somatosensory Evoked Potential Is Negatively Correlated with Motor Function in Parkinson's Disease.
    Kang SY; Ma HI
    J Mov Disord; 2016 Jan; 9(1):35-9. PubMed ID: 26828214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatosensory evoked potentials at rest and during movement in Parkinson's disease: evidence for a specific apomorphine effect on the frontal N30 wave.
    Cheron G; Piette T; Thiriaux A; Jacquy J; Godaux E
    Electroencephalogr Clin Neurophysiol; 1994 Nov; 92(6):491-501. PubMed ID: 7527767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SEPs N30 amplitude in Parkinson's disease and in pharmacologically induced rigidity: relationship with the clinical status.
    Stanzione P; Traversa R; Pierantozzi M; Semprini R; Loberti M; Peppe A; Santilli AM; Bernardi G
    Eur J Neurol; 1997 Jan; 4(1):24-38. PubMed ID: 24283819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amantadine sulfate infusion effect on N30 somatosensory evoked potentials in Parkinson's disease.
    Bostantjopoulou S; Katsarou Z; Georgiadis G; Zafiriou D; Kazis A
    Clin Neuropharmacol; 2002; 25(2):115-8. PubMed ID: 11981240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormality of N30 somatosensory evoked potentials in Parkinson's disease: a multidisciplinary approach.
    Bostantjopoulou S; Katsarou Z; Zafiriou D; Gerasimou G; Alevriadou A; Georgiadis G; Kiosseoglou G; Kazis A
    Neurophysiol Clin; 2000 Dec; 30(6):368-76. PubMed ID: 11191929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The frontal N30 component of the median-derived SEP in patients with predominantly unilateral Parkinson's disease.
    Garcia PA; Aminoff MJ; Goodin DS
    Neurology; 1995 May; 45(5):989-92. PubMed ID: 7746421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curariform peripheral block of muscular tone selectively increases precentral N30 somatosensory evoked potentials component. A pharmacological study carried out on healthy subjects and parkinsonian syndromes.
    Pierantozzi M; Sabato AF; Leonardis F; Marciani MG; Cicardi C; Giacomini P; Bernardi G; Stanzione P
    Exp Brain Res; 2000 Aug; 133(3):368-76. PubMed ID: 10958527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N30 somatosensory evoked potentials in patients with unilateral Parkinson's disease.
    Drory VE; Inzelberg R; Groozman GB; Korczyn AD
    Acta Neurol Scand; 1998 Feb; 97(2):73-6. PubMed ID: 9517855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of deep brain stimulation on the frontal N30 component of somatosensory evoked potentials in advanced Parkinson's disease patients.
    Pierantozzi M; Mazzone P; Bassi A; Rossini PM; Peppe A; Altibrandi MG; Stefani A; Bernardi G; Stanzione P
    Clin Neurophysiol; 1999 Oct; 110(10):1700-7. PubMed ID: 10574285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of N30 somatosensory evoked potentials with spasticity and neurological function after stroke: A cross-sectional study.
    Chen L; Li W; Cheng S; Liang S; Huang M; Lei T; Hu X; Liang Z; Zheng H
    J Rehabil Med; 2021 Sep; 53(9):jrm00223. PubMed ID: 34435643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatosensory evoked potentials and dopaminergic responsiveness to apomorphine and levodopa in parkinsonian patients.
    Miranda M; Castillo JL; Araya F
    Behav Neurol; 1996; 9(3):149-53. PubMed ID: 24487514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The abnormality of N30 somatosensory evoked potential in idiopathic Parkinson's disease is unrelated to disease stage or clinical scores and insensitive to dopamine manipulations.
    Onofrj M; Fulgente T; Malatesta G; Ferracci F; Thomas A; Curatola L; Bollettini F; Ragno M
    Mov Disord; 1995 Jan; 10(1):71-80. PubMed ID: 7885358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The N30 component of somatosensory evoked potentials in patients with dystonia.
    Reilly JA; Hallett M; Cohen LG; Tarkka IM; Dang N
    Electroencephalogr Clin Neurophysiol; 1992; 84(3):243-7. PubMed ID: 1375883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Key Determinants to Quality of Life in Parkinson's Disease Patients: Results from the Parkinson's Disease Biomarker Program (PDBP).
    He L; Lee EY; Sterling NW; Kong L; Lewis MM; Du G; Eslinger PJ; Huang X
    J Parkinsons Dis; 2016 May; 6(3):523-32. PubMed ID: 27258700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormality of Contingent Negative Variation Correlates with Parkinson's Disease Severity.
    Tzvetanov P; Lisichkov I; Rousseff RT; Hegde V; Kostadinov S
    Innov Clin Neurosci; 2022; 19(7-9):71-76. PubMed ID: 36204175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensorimotor and cognitive involvement of the beta-gamma oscillation in the frontal N30 component of somatosensory evoked potentials.
    Cebolla AM; Cheron G
    Neuropsychologia; 2015 Dec; 79(Pt B):215-22. PubMed ID: 26002756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal Spontaneous Brain Activity in Early Parkinson's Disease With Mild Cognitive Impairment: A Resting-State fMRI Study.
    Wang Z; Jia X; Chen H; Feng T; Wang H
    Front Physiol; 2018; 9():1093. PubMed ID: 30154730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of depression and anxiety via patient-assessed tremor severity, not physician-reported motor symptom severity, in patients with Parkinson's disease or essential tremor who have undergone deep brain stimulation.
    Achey RL; Yamamoto E; Sexton D; Hammer C; Lee BS; Butler RS; Thompson NR; Nagel SJ; Machado AG; Lobel DA
    J Neurosurg; 2018 Dec; 129(6):1562-1571. PubMed ID: 29473781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Somatosensory evoked potentials and symptomatic response to dopaminergic drugs in Parkinson's disease].
    Castillo JL; Miranda CM; Araya F; Sáez D
    Rev Med Chil; 1996 Mar; 124(3):301-6. PubMed ID: 9008941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.